Feb 16 |
et al., American Journal of Therapeutics, doi:10.1097/MJT.0000000000002118 | Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial |
| RCT 275 outpatients showing very low hospitalization with combination therapy including ivermectin, doxycycline, vitamin C, vitamin D3, and zinc, with or without famotidine. There was no control group. Only 4 patients were hospitalized wi.. | ||
Jul 31 2025 |
et al., Preprint, 2025 | Rapid recovery of peripheral oxygen saturation in hypoxic COVID-19 patients with ivermectin/doxycycline/zinc multidrug therapy |
| Retrospective 26 consecutive severe COVID-19 outpatients with hypoxia (25 with SpO2 ≤90%) showing rapid oxygen saturation recovery and survival with ivermectin/doxycycline/zinc/vitamin C/vitamin D combination therapy. All 24 patients comp.. | ||
Mar 25 2025 |
et al., The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.78.1_35 | Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part II: Causal inference using the Bradford Hill criteria |
| Critical appraisal of three case series totaling 119 COVID-19 patients with hypoxemia treated with ivermectin-based multidrug protocols in the United States, Zimbabwe, and Nigeria, showing reduced hospitalization and mortality. Authors ap.. | ||
Mar 25 2025 |
et al., The Japanese Journal of Antibiotics, doi:10.11553/antibiotics.78.1_2 | Critical appraisal of multidrug therapy in the ambulatory management of patients with COVID-19 and hypoxemia Part I. Evidence supporting the strength of association |
| Critical appraisal of 119 COVID-19 hypoxemic patients treated with ivermectin-based multidrug protocols in the United States, Zimbabwe, and Nigeria, showing significant hospitalization rate reduction and mortality rate reduction compared .. | ||
Jan 14 2024 |
et al., Pathogens, doi:10.3390/pathogens13010075 | SARS-CoV-2 ORF3a Protein as a Therapeutic Target against COVID-19 and Long-Term Post-Infection Effects |
| Review of the ORF3a protein of SARS-CoV-2 as a therapeutic target for COVID-19 due to its role in viral pathogenesis, triggering cytokine storms, tissue damage, and disease severity. Existing drugs doxycycline, metformin, and ibrutinib ar.. | ||
Jun 17 2022 |
et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.06.016 | COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical tria |
| 64% fewer cases (p=0.04) and 15% improved viral load (p<0.0001). Prophylaxis RCT with 59 zinc + doxycycline, 56 doxycycline, and 57 placebo healthcare workers, showing lower symptomatic cases and significantly improved Ct values with the addition of zinc to doxycycline treatment. Doxycycline 100mg/day .. | ||
Nov 9 2021 |
et al., Biologics, doi:10.3390/biologics2030015 (date from preprint) | Changes in SpO2 on Room Air for 34 Severe COVID-19 Patients after Ivermectin-Based Combination Treatment: 62% Normalization within 24 Hours |
| Retrospective severe COVID-19 patients in Zimbabwe treated with ivermectin, doxycycline, and zinc. For 34 with SpO2 tracking, there was rapid improvement in SpO2, with 55% recovery towards SpO2 97 within 12 hours. The preprint shows furth.. | ||
Oct 19 2021 |
et al., TrialSite News | Combination Therapy For COVID-19 Based on Ivermectin in an Australian Population |
| 92% lower mortality (p=0.03) and 93% lower hospitalization (p<0.0001). Retrospective 600 PCR+ outpatients in Australia treated with ivermectin, zinc, and doxycycline, showing significantly lower mortality and hospitalization with treatment. This trial uses a synthetic control group, and the preliminary repor.. | ||
Sep 30 2021 |
et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00310-6 | Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial |
| 12% higher combined mortality/hospitalization (p=0.59), 51% lower ventilation (p=0.48), 45% lower ICU admission (p=0.36), and 2% lower need for oxygen therapy (p=0.95). RCT 2,508 high-risk patients (aged ≥65 or ≥50 with comorbidities) showing no significant benefit with doxycycline. | ||
Aug 5 2021 |
et al., In Silico Pharmacology, doi:10.1007/s40203-026-00576-w (date from preprint) | Ivermectin and Doxycycline combination as a promising anti-viral drug candidate: an in-silico and DFT study |
| In silico study showing strong binding affinity of ivermectin and doxycycline for SARS-CoV-2 main protease 3CLpro, and increased binding affinity for the combination of both. | ||
Jul 7 2021 |
et al., medRxiv, doi:10.1101/2021.07.06.21259924 | Effectiveness of ivermectin-based multidrug therapy in severely hypoxic, ambulatory COVID-19 patients |
| 100% lower mortality (p=0.04) and 100% lower hospitalization (p=0.001). Small study of 24 consecutive patients in serious condition (9 days post symptoms, mean SpO2 87.4) using combined treatment with ivermectin, doxycycline, zinc, vitamin D, and vitamin C, showing no mortality or hospitalization with treatme.. | ||
Jun 18 2021 |
et al., PLOS One, doi:10.1371/journal.pone.0252302 | An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia |
| In vitro study of combinations of drugs showing antiviral efficacy of HCQ alone and in combination with AZ, favipiravir, and doxycycline. No high levels of cytotoxicity were observed, and authors conclude that using a combination of drugs.. | ||
Apr 29 2021 |
et al., Cureus, doi:10.7759/cureus.14761 | Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan |
| 50% lower mortality (p=0.03). Retrospective 165 hospitalized patients in Pakistan showing unadjusted lower mortality with combined ivermectin and doxycycline treatment. Details of the ivermectin group compared to other patients are not provided, however ivermectin was.. | ||
Dec 11 2020 |
et al., International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 | Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh |
| Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again. | ||
Nov 14 2020 |
et al., IAIM, 2020, 7:10, 177-182 | Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2 |
| 21% faster recovery (p=0.03) and 16% shorter hospitalization (p=0.01). 100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment. | ||
Oct 26 2020 |
et al., Iraqi Journal of Medical Science, 19:1 | Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq |
| 92% lower mortality (p=0.03), 83% lower progression (p=0.07), and 41% faster recovery (p=0.0001). RCT 70 ivermectin+doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment. Earlier treatment was more successful. For ethical reasons, critical patients were all in the treatment .. | ||
Oct 9 2020 |
et al., Journal of International Medical Research, doi:10.5061/dryad.qjq2bvqf6 (date from preprint) | Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial |
| 86% lower mortality (p=0.25), 57% lower progression (p=0.001), 94% improved recovery (p<0.0001), and 39% improved viral clearance (p=0.002). RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. 183 treatment and 183 control patients with no deaths in the treatment arm vs. 3 in the control arm (the 3 control deaths are n.. | ||
Jul 31 2020 |
et al., Journal of Bangladesh College of Physicians and Surgeons, doi:10.3329/jbcps.v38i0.47512 | A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline |
| Case study of 100 patients treated with ivermectin and doxycycline, with no ICU admission, deaths, or serious side effects reported. | ||
Jul 31 2020 |
et al., J. Bangladesh Coll. Phys. Surg. 38, 5-9, doi:10.3329/jbcps.v38i0 | Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients |
| Comparison of 200 patients treated with ivermectin + doxycycline and 200 treated with HCQ + AZ. The HCQ + AZ group had more severe cases at baseline. Viral clearance was faster with ivermectin + doxycycline, however ivermectin clearance r.. | ||
Jul 9 2020 |
, D., American Chemical Society (ACS), doi:10.26434/chemrxiv.12630539.v1 | A Combination of Ivermectin and Doxycycline Possibly Blocks the Viral Entry and Modulate the Innate Immune Response in COVID-19 Patients |
| In silico study showing that a combination of ivermectin and doxycycline may inhibit SARS-CoV-2 infection through binding to multiple viral proteins as well as the host ACE2 receptor. Authors suggest that ivermectin may block viral entry .. | ||